Cell Wall Synthesis Inhibitors - Microbiology

1. A patient with atypical pneumonia caused by Mycoplasma pneumoniae is not responding to treatment with ceftriaxone. What is the fundamental microbiological basis for the ineffectiveness of ceftriaxone against this organism?
   Answer: The organism lacks a peptidoglycan cell wall. Mycoplasma species are intrinsically resistant to all cell wall synthesis inhibitors, including beta-lactams like ceftriaxone, because they do not have a peptidoglycan cell wall. The drug's target is absent in the organism. The other options describe valid resistance mechanisms in other bacteria but are not the reason for the intrinsic resistance of Mycoplasma.
2. Cycloserine is a second-line antitubercular agent that acts as a structural analog of D-alanine. Its bacteriostatic effect results from the competitive inhibition of which pair of enzymes crucial for peptidoglycan synthesis?
   Answer: Alanine racemase and D-alanyl-D-alanine synthetase Cycloserine mimics the structure of D-alanine. It competitively inhibits two essential cytoplasmic enzymes: alanine racemase, which converts L-alanine to D-alanine, and D-alanyl-D-alanine synthetase (or ligase), which joins two D-alanine molecules to form the dipeptide needed for the pentapeptide chain. This starves the cell of the necessary D-Ala-D-Ala precursor. InhA and KasA are involved in mycolic acid synthesis (isoniazid targets). Transpeptidase and transglycosylase are later, periplasmic targets. MurA/B are earlier cytoplasmic steps not involving D-alanine.
3. Fosfomycin is a broad-spectrum antibiotic that acts very early in the peptidoglycan synthesis pathway. It functions as an analog of phosphoenolpyruvate (PEP) and irreversibly inactivates the enzyme MurA. This action directly prevents which biochemical reaction?
   Answer: The transfer of an enolpyruvyl group to UDP-N-acetylglucosamine. Fosfomycin inhibits the enzyme UDP-N-acetylglucosamine enolpyruvyl transferase (MurA). This enzyme catalyzes the first committed step in peptidoglycan biosynthesis: the transfer of an enolpyruvyl group from phosphoenolpyruvate (PEP) to the 3'-hydroxyl group of UDP-N-acetylglucosamine (UDP-NAG). This reaction forms UDP-N-acetylglucosamine-enolpyruvate, which is subsequently reduced to form UDP-N-acetylmuramic acid (UDP-NAM). By blocking this initial step, fosfomycin halts the entire downstream pathway.
4. A physician is treating an Enterococcus faecalis infection with ampicillin, a beta-lactam. To improve bactericidal activity, a second agent is added. Which of the following agents would create a synergistic effect by inhibiting a preceding, sequential step within the same peptidoglycan synthesis pathway?
   Answer: Fosfomycin The question specifies synergy by inhibiting a sequential step in the same pathway. Ampicillin inhibits the final transpeptidation step of peptidoglycan synthesis. Fosfomycin inhibits MurA, which catalyzes the very first committed step of peptidoglycan synthesis in the cytoplasm. Therefore, it targets a preceding, sequential step. While gentamicin is famously synergistic with beta-lactams against enterococci, its mechanism is inhibition of protein synthesis, and the synergy arises because the cell-wall-active agent facilitates gentamicin's entry to the ribosome, not because they target sequential steps in one pathway.
5. The protein product of the mecA gene, PBP2a, confers broad beta-lactam resistance through which mechanism?
   Answer: Functioning as a substitute transpeptidase with low binding affinity for beta-lactam antibiotics. The mecA gene encodes Penicillin-Binding Protein 2a (PBP2a). PBP2a is a transpeptidase that, due to its altered active site structure, has a very low affinity for nearly all beta-lactam antibiotics. It can continue to catalyze the essential cross-linking of the cell wall even when the bacterium's other native PBPs are inactivated by the drug. Beta-lactamase production and alteration of the precursor terminus are distinct resistance mechanisms seen in other bacteria.
6. Ethambutol is a key component of multi-drug therapy for tuberculosis. Its mechanism of action involves the specific inhibition of an enzyme complex responsible for which process in mycobacterial cell wall construction?
   Answer: The polymerization of arabinan into arabinogalactan. Ethambutol inhibits the mycobacterial arabinosyl transferases encoded by the embAB genes. These enzymes are essential for the polymerization of D-arabinofuranose residues into the arabinan domains of both arabinogalactan (AG) and lipoarabinomannan (LAM). Disruption of AG synthesis prevents the attachment of the outer mycolic acid layer to the peptidoglycan, compromising the entire cell wall structure. Mycolic acid synthesis is inhibited by isoniazid.
7. Telavancin, a lipoglycopeptide antibiotic, exhibits enhanced bactericidal activity compared to vancomycin. This is due to a dual mechanism of action. What is the second mechanism, in addition to the inhibition of peptidoglycan polymerization that it shares with vancomycin?
   Answer: Anchoring in the cell membrane, causing depolarization and increased permeability. Telavancin is a derivative of vancomycin that contains a lipid tail. This lipophilic moiety allows the drug to anchor into the bacterial cytoplasmic membrane. This anchoring disrupts the membrane's structure and leads to rapid depolarization of the membrane potential and increased permeability. This membrane-damaging effect is the second mechanism of action, which contributes to its potent, rapid bactericidal activity, complementing its primary action of inhibiting cell wall synthesis via D-Ala-D-Ala binding.
8. The monobactam antibiotic aztreonam has an unusual spectrum of activity, targeting aerobic Gram-negative bacteria while having virtually no effect on Gram-positive bacteria or anaerobes. This high degree of specificity is primarily due to its:
   Answer: preferential and high-affinity binding to penicillin-binding protein 3 (PBP3) of aerobic Gram-negatives. Aztreonam's narrow spectrum is a direct result of its target specificity. It binds with very high affinity to penicillin-binding protein 3 (PBP3) of aerobic Gram-negative rods (like Enterobacteriaceae and P. aeruginosa). PBP3 is essential for cell septum formation during division. Aztreonam has poor affinity for the PBPs of Gram-positive bacteria and anaerobic bacteria, rendering it ineffective against them. While entry via porins is necessary, the defining feature is its selective interaction with a specific PBP.
9. Which antibiotic most likely caused this effect by sterically hindering the transglycosylase enzyme from adding new disaccharide units to the polymer?
   Answer: Vancomycin Vancomycin binds to the D-Ala-D-Ala terminus of the lipid II precursor. This large molecule then acts as a steric shield, physically blocking the active sites of both the transglycosylase (which elongates the glycan chain) and the transpeptidase (which cross-links the peptides). Penicillin and ceftriaxone only inhibit the transpeptidase. Bacitracin would prevent the formation or transport of the lipid II precursor itself, an earlier step not described in the assay's outcome.
10. Which property of meropenem is the primary reason for its stability and continued activity against this ESBL-producing strain?
    Answer: A molecular structure that is highly resistant to hydrolysis by the ESBL enzyme. Carbapenems, such as meropenem, possess a unique stereochemical configuration at position C6 (a trans-hydroxyethyl group instead of an acylamino side chain) that confers significant resistance to hydrolysis by many beta-lactamases, including ESBLs. While binding profiles and porin entry are relevant to their overall activity, their stability in the face of these enzymes is the key reason for their effectiveness when other beta-lactams fail.
11. The bactericidal, rather than bacteriostatic, activity of beta-lactam antibiotics against susceptible bacteria is dependent not only on the inhibition of transpeptidases but also on the continued, unregulated activity of which endogenous bacterial enzymes?
    Answer: Autolysins When beta-lactams inhibit peptidoglycan synthesis, the cell's own autolytic enzymes (murein hydrolases), which are normally involved in controlled cell wall cleavage for growth and division, continue to function. This creates an imbalance between synthesis and degradation, leading to progressive weakening of the cell wall, loss of structural integrity, and eventual osmotic lysis. This process is often termed 'autolytic death'.
12. What is the most probable fate of these protoplasts when incubated in the penicillin-containing medium?
    Answer: They will remain viable because penicillin's target is absent. Protoplasts are bacterial cells from which the cell wall has been completely removed. Penicillin acts by inhibiting enzymes involved in peptidoglycan synthesis. Since protoplasts lack a cell wall and are not actively synthesizing one (especially in a resting state), penicillin has no target. As long as the external medium is osmotically stable (hypertonic) to prevent lysis, the protoplasts will remain viable and unaffected by the presence of penicillin.
13. Vancomycin demonstrates excellent activity against many Gram-positive pathogens like Staphylococcus aureus and Enterococcus faecalis, but it is ineffective against most Gram-negative organisms such as Pseudomonas aeruginosa. This limitation in its spectrum of activity is primarily a consequence of:
    Answer: the physical inability of the large vancomycin molecule to penetrate the Gram-negative outer membrane. Vancomycin is a large glycopeptide molecule with a molecular weight of approximately 1450 Da. The outer membrane of Gram-negative bacteria contains porin channels that typically restrict passage to smaller, hydrophilic molecules (usually < 600 Da). Vancomycin is too large to pass through these porins to reach its target, the D-Ala-D-Ala of peptidoglycan precursors located in the periplasmic space. This physical barrier is the principal reason for the intrinsic resistance of most Gram-negative bacteria.
14. This genetic modification would be expected to confer the highest level of resistance to which of the following antibiotics?
    Answer: Vancomycin Vancomycin's mechanism of action is the specific binding to the D-Ala-D-Ala terminus of the NAM-pentapeptide precursor. The periplasmic dipeptidase would cleave this terminus, effectively removing the binding site for vancomycin and preventing its action. Penicillin binds to the transpeptidase enzyme, not the precursor, so its target remains. Daptomycin targets the cell membrane, and linezolid targets the ribosome; neither would be affected by this modification.
15. The accumulation of this specific intermediate suggests the antibiotic is most likely which of the following?
    Answer: Bacitracin The accumulation of the completed cytoplasmic precursor, UDP-NAM-pentapeptide, indicates that its synthesis is intact but its transport to the periplasm is blocked. This transport requires the lipid carrier bactoprenol phosphate. Bacitracin inhibits the dephosphorylation of bactoprenol pyrophosphate back to bactoprenol phosphate, thus trapping the carrier in an unusable form and preventing the transport of new precursors. Penicillin and vancomycin act extracellularly. Fosfomycin acts in the cytoplasm but at a much earlier step (inhibiting MurA), which would prevent the formation of UDP-NAM-pentapeptide itself.
16. Isoniazid is a prodrug that, once activated by the mycobacterial catalase-peroxidase enzyme KatG, is a potent inhibitor of Mycobacterium tuberculosis cell wall synthesis. The activated form of isoniazid covalently binds to and inactivates an enzyme essential for the synthesis of which specific cell wall component?
    Answer: Mycolic acids Activated isoniazid's primary target is the enoyl-acyl carrier protein reductase, known as InhA. This enzyme is a critical component of the fatty acid synthase II (FAS-II) system, which is responsible for synthesizing the very long (C60-C90) mycolic acids that form the protective, waxy outer layer of the mycobacterial cell envelope. Arabinogalactan is the target of ethambutol.
17. The efficacy of the beta-lactam antibiotic class relies on the strained beta-lactam ring, which functions as a structural mimic of a key component in the cell wall synthesis pathway. This mimicry allows the antibiotic to bind and inactivate transpeptidases. What component is being mimicked?
    Answer: The D-alanyl-D-alanine peptide terminus The beta-lactam ring is a structural analog of the D-alanyl-D-alanine terminus of the peptidoglycan pentapeptide. The transpeptidase (penicillin-binding protein) active site recognizes this structure and attempts to cleave the amide bond in the beta-lactam ring. This results in the formation of a stable, covalent acyl-enzyme intermediate, which effectively inactivates the enzyme and halts cell wall cross-linking.
18. Which of the following cell wall synthesis inhibitors would most likely retain its activity against this highly resistant organism?
    Answer: Bacitracin The insensitive transpeptidases confer resistance to all beta-lactams, including oxacillin and ceftaroline. The D-Ala-D-Lactate terminus confers resistance to glycopeptides like vancomycin, which cannot bind effectively. Bacitracin, however, acts on an entirely different and earlier step: it inhibits the dephosphorylation of the lipid carrier bactoprenol pyrophosphate. This process is essential for transporting peptidoglycan precursors across the membrane and is unaffected by the two resistance mechanisms described, so bacitracin would likely still be effective.
19. How would this specific mutation most likely alter the bacterium's susceptibility profile to penicillin and vancomycin?
    Answer: Significantly decreased susceptibility to vancomycin but minimal change in susceptibility to penicillin. Vancomycin's mechanism involves binding directly to the D-Ala-D-Ala terminus of the peptidoglycan precursor. Changing this terminus to D-Ala-D-Ser dramatically reduces the binding affinity of vancomycin, conferring resistance. Penicillin, a beta-lactam, inhibits the transpeptidase enzyme (PBP) by acting as a structural analog of the D-Ala-D-Ala substrate. While the enzyme's substrate has changed, the enzyme itself remains the primary target. Penicillin can still bind to and acylate the PBP active site, so its efficacy is largely retained, unlike vancomycin's.

Start this quiz